2013年11月
Determination of galactosamine impurities in heparin sodium using fluorescent labeling and conventional high-performance liquid chromatography
BIOLOGICALS
- 巻
- 41
- 号
- 6
- 開始ページ
- 355
- 終了ページ
- 363
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1016/j.biologicals.2013.06.002
- 出版者・発行元
- ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
Heparin is a sulfated glycosaminoglycan (GAG), which contains N-acetylated or N-sulfated glucosamine (GlcN). Heparin, which is generally obtained from the healthy porcine intestines, is widely used as an anticoagulant during dialysis and treatments of thrombosis such as disseminated intravascular coagulation. Dermatan sulfate (DS) and chondroitin sulfate (CS), which are galactosamine (GalN)-containing GAGs, are major process-related impurities of heparin products. The varying DS and CS contents between heparin products can be responsible for the different anticoagulant activities of heparin. Therefore, a test to determine the concentrations of GalN-containing GAG is essential to ensure the quality and safety of heparin products. In this study, we developed a method for determination of relative content of GalN from GalN-containing GAG in heparin active pharmaceutical ingredients (APIs). The method validation and collaborative study with heparin manufacturers and suppliers showed that our method has enough specificity, sensitivity, linearity, repeatability, reproducibility, and recovery as the limiting test for GalN from GalN-containing GAGs. We believe that our method will be useful for ensuring quality, efficacy, and safety of pharmaceutical heparins. On July 30, 2010, the GalN limiting test based on our method was adopted in the heparin sodium monograph in the Japanese Pharmacopoeia. (C) 2013 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.biologicals.2013.06.002
- ISSN : 1045-1056
- eISSN : 1095-8320
- PubMed ID : 23827519
- Web of Science ID : WOS:000328596800003